What the mouse work found
In Lee’s 2015 study, mice eating a high-fat diet gained less weight with MOTS-c than without it. MOTS-c also helped prevent insulin resistance: the body becoming less able to respond to insulin, which helps control blood sugar.
That result belongs to the animals and conditions studied. It is not a forecast of weight loss for a person.
What has not been shown
As of September 30, 2026, no published treatment trial showed how injected MOTS-c affects weight or blood sugar in people.
Ask to see the human result behind a claim about weight or blood sugar. A mouse study cannot supply that result.
A registered trial is a question being tested
The MOTS-MET record on ClinicalTrials.gov describes a study in adults with prediabetes and extra weight.
Prediabetes is blood sugar above the usual level but below the range for diabetes.
As of September 30, 2026, the study listing had no results to read.
Ask about the concern behind the search
Bring the weight or blood sugar concern to a doctor as a problem to assess. Ask what evidence supports the care options for that problem.
As of September 30, 2026, the US drug agency (FDA) notes in its MOTS-c review that approved medicines exist for obesity, a medical condition involving excess body fat.
Keep this in mind
The mouse findings provide a reason to study MOTS-c, not a proven weight or blood sugar treatment for people.
A question to take
Was the claimed weight or blood sugar benefit tested in people receiving MOTS-c?
Open my notes